ERBB2 and breast cancer: Our results suggest that T-DM1 utilization in the EU5 and Canada has the potential to change the epidemiology of HER2-positive BC by preventing a substantial number of women with eBC and residual disease following neoadjuvant therapy from relapsing to mBC.